CTI BioPharma Corp - Company Profile
Powered by
All the data and insights you need on CTI BioPharma Corp in one report.
- Save hours of research time and resources with
our up-to-date CTI BioPharma Corp Strategy Report
- Understand CTI BioPharma Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
CTI BioPharma Corp (CTI BioPharma), a subsidiary of Swedish Orphan Biovitrum AB, is a biopharmaceutical company focused on developing, acquiring, and commercializing innovative treatments for cancer. License agreements focus on R&D activities and lead product VONJO, patent portfolio are its major strengths while increase in debt could be a cause for concern to the company. The company could benefit from the growing incidence of cancer, rising healthcare expenditure in the US, and pipeline products. However, tightening regulations, Lack of manufacturing facilities and intense competition may hinder its future growth.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer